Share：
Share this content in WeChat
X
[Chinese][PDF]94279
• Clinical Article •
Application value of IVIM in predicting MGMT promoter methylation status in high-grade gliomas
TIAN Bowen  YANG Guoqiang  QIN Jiangbo  ZHANG Hui 

Cite this article as: Tian BW, Yang GQ, Qin JB, et al. Application value of IVIM in predicting MGMT promoter methylation status in high-grade gliomas. Chin J Magn Reson Imaging, 2020, 11(7): 506-510. DOI:10.12015/issn.1674-8034.2020.07.006.


[Abstract] Objective: Studies on intramoxin incoherent motion (IVIM) in predicting methylation of the high-grade glioma O6-methylguanine-DNA methyltransferase (MGMT) promoter application value of status.Materials and Methods: Thirty-four patients with high-grade glioma confirmed by pathology were collected, including 19 cases of WHO Ⅲ and 15 cases of Ⅳ. All patients underwent conventional craniocerebral MRI scans and IVIM scans before surgery. Tissue area, obtain true diffusion coefficient (D), perfusion related diffusion coefficient (D*), perfusion fraction (f), and divide the measured value of the tumor parenchyma by the normal brain on the opposite side In the substantial area, the corrected parameter values are obtained: relative D (relative D), relative D* (relative D*), and relative f (relative f). Two-sample independent t test is used to analyze the methylation group and non-methyl group of the MGMT promoter. The correction parameter differences between the groups were calculated, and receiver operating characteristic (ROC) curves were plotted to calculate the threshold, sensitivity, and specificity.Results: The rD and rf values of MGMT promoter methylation group in high-grade glioma was higher than that in non-methylation group, and rD* value were lower than those in non-methylation group. The differences were statistically significant (P<0.05). The area under the ROC curve of rD, rD*, and rf values are: 0.856, 0.814, and 0.719; the thresholds are: 1.703, 1.058, and 1.756; the sensitivities are: 84.2%, 89.5%, and 63.2%; the specificities are: 73.3%, 60.0%, 93.3%.Conclusions: IVIM can non-invasively evaluate the methylation status of MGMT promoter in high-grade gliomas. Among them, rD* has high sensitivity, which can help guide patients' personalized diagnosis and treatment programs and assess prognosis.
[Keywords] glioma；magnetic resonance imaging；DNA repair enzymes；prediction；differential diagnosis

TIAN Bowen College of Medical Imaging, Shanxi Medical University, Taiyuan 030001, China

YANG Guoqiang Department of Radiology, First Hospital of Shanxi Medical University, Taiyuan 030001, China

QIN Jiangbo Department of Radiology, First Hospital of Shanxi Medical University, Taiyuan 030001, China

ZHANG Hui* Department of Radiology, First Hospital of Shanxi Medical University, Taiyuan 030001, China

*Correspondence to: Zhang H, E-mail: zhanghui_mr@163.com

Conflicts of interest   None.

Received  2019-12-31
Accepted  2020-03-27
DOI: 10.12015/issn.1674-8034.2020.07.006
Cite this article as: Tian BW, Yang GQ, Qin JB, et al. Application value of IVIM in predicting MGMT promoter methylation status in high-grade gliomas. Chin J Magn Reson Imaging, 2020, 11(7): 506-510. DOI:10.12015/issn.1674-8034.2020.07.006.

[1]
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol, 2016, 131(6): 803-820.
[2]
Philteos J, Karmur BS, Mansouri A. MGMT Testing in Glioblastomas: Pitfalls and Opportunities. Am J Clin Oncol, 2019, 42(2): 117-122.
[3]
Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med, 2005, 352(10): 997-1003.
[4]
Bell EH, Zhang P, Fisher BJ, et al. Association of MGMT promoter methylation status with survival outcomes in patients with high-risk glioma treated with radiotherapy and temozolomide: an analysis from the NRG Oncology/RTOG 0424 trial. JAMA Oncol, 2018, 4(10): 1405-1409.
[5]
Patel AP, Tirosh I, Trombetta JJ, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science, 2014, 344(6190): 1396-1401.
[6]
Nabors LB, Portnow J, Ammirati M, et al. NCCN guidelines insights: central nervous system cancers, version 1.2017. J Natl Compr Canc Netw, 2017, 15(11): 1331-1345.
[7]
Roszkowski K, Furtak J, Zurawski B, et al. Potential role of methylation marker in glioma supporting clinical decisions. Int J Mol Sci, 2016, 17(11): 1876.
[8]
Vanessa NH, Scott IS, David EP, et al. Use of new imaging techniques to predict tumour response to therapy. Lancet Oncol, 2010, 11(1): 92-102.
[9]
Bihan DL, Breton E, Lallemand D, et al. MR imaging of incoherent motion: application to diffusion and perfusion in neurologic disorders. Radiology, 1986, 161(2): 401-407.
[10]
Reifenberger G, Hentschel B, Felsberg J, et al. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer, 2012, 131(6): 1342-1350.
[11]
Christian F, Milena C, Marion R, et al. Mosimann, Philippe Maeder, Reto Meuli, Max Wintermark. IVIM perfusion fraction is prognostic for survival in brain glioma. Clin Neuroradiol, 2017, 27(4): 485-492.
[12]
郝凤玲，吴慧，牛广明．单指数、双指数、拉伸指数模型DWI在胶质瘤术前分级中的应用．磁共振成像, 2019, 10(06): 401-405.
[13]
Moon WJ, Choi JW, Roh HG, et al. Imaging parameters of high grade gliomas in relation to the MGMT promoter methylation status: the CT, diffusion tensor imaging, and perfusion MR imaging. Neuroradiology, 2012, 54(6): 555-563.
[14]
王振，许在华，孙靖驰，等. IDH1基因突变及MGMT基因启动子甲基化在胶质瘤中的临床意义．肿瘤学杂志, 2018, 24(11): 1118-1121.
[15]
Rundle-Thiele D, Day B, Stringer B, et al. Using the apparent diffusion coefficient to identifying MGMT promoter methylation status early in glioblastoma: importance of analytical method. J Med Radiat Sci, 2015, 62(2): 92-98.
[16]
Ryoo I, Choi SH, Kim JH, et al. Cerebral blood volume calculated by dynamic susceptibility contrast-enhanced perfusion MR imaging: preliminary correlation study with glioblastoma genetic profiles. PLoS One, 2013, 8: e71704.
[17]
Chahal M, Xu YX, Lesniak D, et al. MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib. Neuro oncol, 2010, 12(8): 822-833.
[18]
王嵇，李磊，华小兰，等．体素内不相干运动成像与动态对比增强磁共振成像评价胶质瘤灌注的应用价值．上海医学, 2018, 41(4): 223-227.
[19]
Ahn SS, Shin NY, Chang JH, et al. Prediction of methylguanine methyltransferase promoter methylation in glioblastoma using dynamic contrast-enhanced magnetic resonance and diffusion tensor imaging. J Neurosurg, 2014, 121(2): 367-373.
[20]
Mills SJ, Patankar TA, Haroon HA, et al. Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? AJNR Am J Neuroradiol, 2006, 27(4): 853-858.

PREV The value of ESWAN in diagnosis and differential diagnosis of endometrial carcinoma and endometrial polyp
NEXT A research of the resting state network in patients with chronic neck and shoulder pain of cervical spondylosis
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn